摘要
目的观察索磷布韦维帕他韦治疗丙型病毒性肝炎的临床疗效及其对肝功能的影响。方法选取2015—2020年信宜市人民医院收治的丙型病毒性肝炎患者46例作为研究对象,采用随机数字表法分为对照组和试验组,各23例。对照组采用利巴韦林联合干扰素治疗,疗程为48周;试验组采用索磷布韦维帕他韦治疗,疗程为12周。比较2组临床疗效,治疗前后肝功能指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、白蛋白(Alb)、总胆红素(TBiL)、谷氨酰转氨酶(GGT)水平及凝血酶原活动度(PAT)]、随访6个月疾病复发率及不良反应发生率。结果试验组病毒应答率为95.65%,高于对照组的73.91%(χ^(2)=4.212,P=0.040)。治疗后,2组AST、ALT水平及试验组TBiL、GGT水平低于治疗前,2组PAT高于治疗前,且试验组AST、ALT、Alb、TBiL、GGT水平低于对照组,PAT高于对照组(P<0.05)。2组随访6个月疾病复发率比较,差异无统计学意义(P>0.05)。试验组治疗期间不良反应发生率为8.70%,与对照组的17.39%比较,差异无统计学意义(χ^(2)=0.767,P=0.381)。结论索磷布韦维帕他韦治疗丙型病毒性肝炎的临床疗效确切,可有效提高病毒应答率,改善患者肝功能,降低疾病复发率,且安全性较高。
Objective To explore the curative effect of sobuvir dipivoxil in the treatment of virus hepatitis C and its impact on liver function of patients.Methods A total of 46 patients with viral hepatitis C admitted to People′s Hospital of Xinyi from 2015 to 2020 as the research objects,and they were divided into control group and experimental group by random number table method,23 cases in each group.Patients in control group were treated with ribavirin and interferon for 48 weeks,patients in experimental group were treated with sobuvir dipivoxil for 12 weeks.Clinical effect,liver function indexes(AST,ALT,Alb,TBiL,GGT and PAT)before and after treatment,disease recurrence rate after 6 months follow-up,and incidence of adverse reactions were compared between the two groups.Results Virus response rate of experimental group was 95.65%,which was higher than 73.91%of control group(χ^(2)=4.212,P=0.040).After treatment,levels of AST,ALT in the two groups and levels of Alb,TBiL,GGT in experimental group were lower than those before treatment,PAT in the two groups was higher than that before treatment,and levels of AST,ALT,TBiL,GGT in experimental group were lower than those before treatment,PAT was higher than that in control group(P<0.05).There was no significant difference of disease recurrence rate after 6 months follow-up between the two groups(P>0.05).There was no significant difference of incidence of adverse reactions between the experimental group(8.70%)and the control group(17.39%)(χ^(2)=0.767,P=0.381).Conclusion Sobuvir dipivoxil has an exact clinical effect in the treatment of virus hepatitis C,it can promote virus response rate,improve liver function of patients,reduce disease recurrence rate,and with higher safety.
作者
伍灵南
龙云升
黄志泳
何龙芳
梁宗柱
WU Lingnan;LONG Yunsheng;HUANG Zhiyong;HE Longfang;LIANG Zongzhu(Department of Infectious Disease,People′s Hospita l of Xinyi,Xinyi 525300,China)
出处
《临床合理用药杂志》
2022年第36期27-30,共4页
Chinese Journal of Clinical Rational Drug Use
